Organizations should evaluate member voluntariness, clinical independence, eligible populations, contracting roles, fiduciary considerations, privacy, security, quality governance, sourcing evidence, complaints, exceptions, and a validated cost methodology. Program-level eligibility never approves an individual medicine or shipment, and savings should remain qualitative until supported by PharmaViaRx-specific data.